Skip to main content
ARTELO BIOSCIENCES, INC. logo

ARTELO BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ARTL ISIN · US04301G7060 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2022-02-04 Major Shareholding Noti…
Country US United States of America
Listing US ARTL

About ARTELO BIOSCIENCES, INC.

https://artelobio.com/

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's scientific approach is centered on modifying lipid-signaling pathways, particularly by modulating the endocannabinoid system. Its primary therapeutic focus is on developing improved treatments for patients with cancer and other serious diseases. Artelo is advancing a diverse portfolio of drug candidates through its development pipeline to address unmet medical needs.

Recent filings

Filing Released Lang Actions
ARTL 13G/A
Major Shareholding Notification
2022-02-04 English
FORM 10-Q
Interim / Quarterly Report Q1 2022
2022-01-12 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The specific item reported is Item 5.02, which relates to the departure or appointment of directors or certain officers and compensatory arrangements. The content describes a stock option grant to the principal executive officer, which is a management compensation event. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is not a proxy statement or voting result announcement. The key content is about management compensation and appointment-related information. Therefore, the most appropriate classification is "Board/Management Information (MANG)". The document length is 3522 characters, which is relatively short but contains substantive information about management changes and compensation, not just an announcement of a report publication or a certification. Confidence is high due to clear identification of the filing type and content.
2021-12-07 English
FORM 4 SUBMISSION
Director's Dealing
2021-12-07 English
FORM 10-K
Annual Report FY 2021
2021-11-29 English
FORM 8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a notice of delisting risk due to non-compliance with Nasdaq's minimum bid price rule and a change in the company's fiscal year end. There is no detailed financial data or comprehensive report content, but rather regulatory announcements about listing status and corporate governance changes. This fits the definition of a Delisting Announcement (DLST) because the primary focus is on the Nasdaq notice regarding potential delisting due to bid price non-compliance. The fiscal year change is a secondary governance update but does not dominate the filing. The document length is about 5242 characters, which is sufficient for a substantive announcement but not a full financial report. Therefore, the best classification is DLST with high confidence.
2021-09-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.